Product Name :Tirzepatide
CAS No.:2023788-19-2
0Purity : 99.0%min. HPLC
Appearance:  White Crystalline Lyophilized Powder
Typical use: Weight loss peptides
Shelf Life :24Months
Storage:Refrigeration keep dry and away from light.
 

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. 
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid moiety. Its half-life of approximately 5 days allows once-weekly subcutaneous administration. A phase 2b trial involving patients with type 2 diabetes showed that those who received tirzepatide had dose-dependent reductions in the glycated hemoglobin level and weight at 26 weeks.
Once-weekly injectable semaglutide, a selective GLP-1 receptor agonist, is approved for the treatment of type 2 diabetes at doses up to 1 mg. In trials involving patients who received semaglutide, the mean reductions in the glycated hemoglobin level have been reported to be as high as 1.8 percentage points and the mean reductions in body weight have been reported to be as high as 6.5 kg.
We conducted the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, and 15 mg with those of semaglutide at a dose of 1 mg in patients with type 2 diabetes that had been inadequately controlled with metformin monotherapy


Description of Liraglutide CAS 204656-20-2

 I ntroduction for   Liraglutide CAS 204656-20-2
Liraglutide (NN2211) is a long-acting gluca on-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxen  as a treatment for obesity in adults with at least one weight-related comorbid condition.
Liraglutide was approved for treatment of type 2 diabetes by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010. More recently, Liraglutide was approved by the FDA on December 23, 2014 for treatment for obesity in adults with some related comorbidity.

FUNCTION

Liraglutide is a once-daily injectable derivative of the human incretin glucagon-like peptide-1 (GLP-1), for the treatment of type
2 diabetes or obesity.

APPLICATION

1.Treating type 2 diabetes.
2.Treating obesity.

1. Glutamine Powder is the most prevalent amino acid in the bloodstream.

2. Glutamine Powder is involved in more metabolic processes than any other amino acid.

3. Glutamine Powder is converted to glucose when more glucose is required by the body as an energy source.

4. Glutamine Powder also plays a part in maintaining proper blood glucose levels and the right pH range.

5. Glutamine Powder serves as a source of fuel for cells lining the intestines. Without it, these cells waste away.

6. Glutamine Powder assists in maintaining the proper acid/alkaline balance in the body, and is the basis of the building
blocks for the synthesis of RNA and DNA.

TOP Purity Raw Powder for Bodybuiler Supplement

 
Appearance: White crystalline powder 
Uses: pharmaceutical raw materials, the hormones
Package: 500G/bag 
Assay: 99%